Augmentation of Tendon-to-Bone Healing With a Magnesium-Based Bone Adhesive

Lawrence V. Gulotta, MD, David Kovacevic, Liang Ying, John Ehteshami, MD, Scott Montgomery, and Scott A. Rodeo,* MD
From the Laboratory for Soft Tissue Research, Hospital for Special Surgery, New York, New York

Background: Healing of an anterior cruciate ligament graft in a bone tunnel occurs by formation of fibrous scar tissue, which is weaker than the normal fibrocartilaginous insertion.

Hypothesis: We hypothesized that a magnesium-based bone adhesive would improve tendon-to-bone healing in a rabbit anterior cruciate ligament reconstruction model.

Study Design: Controlled laboratory study.

Methods: Thirty-five New Zealand White rabbits underwent bilateral anterior cruciate ligament reconstructions with semitendinosus autografts. A total of 12.5 g of bone adhesive was placed in the intraosseous tunnel around the graft in one limb, while the tunnels in the contralateral limb received no implant. Sixteen animals each were sacrificed at 3 weeks and at 6 weeks (12 biomechanical testing/4 histology). Outcomes included semiquantitative histologic analyses for new cartilage formation and fibrous tissue formation in the tendon-bone interface, microcomputed tomography to quantify new bone formation along the bone tunnel, and biomechanical testing of load-to-failure and stiffness. Three animals were sacrificed at time 0 to confirm adequate tunnel fill with the bone adhesive on microcomputed tomography.

Results: All specimens had adequate tunnel fill with the bone adhesive at time 0. Application of the bone adhesive resulted in more cartilage formation and less fibrous tissue formation at the tendon-bone interface at 6 weeks compared with controls (P < .05). There was significantly more bone formation in the tibia of the treated limbs at 6 weeks (P = .01). The load-to-failure was significantly higher in the treated group at 6 weeks (71.8 ± 31.8 N vs 43.4 ± 14.8 N; P = .04). There were no differences in stiffness at either time point, and there were no differences at 3 weeks in any outcome variable.

Conclusion: The magnesium-based bone adhesive improves tendon-to-bone healing based on histologic and biomechanical testing at 6 weeks in a rabbit model of anterior cruciate ligament reconstruction.

Clinical Relevance: Further studies are needed to investigate the clinical potential of this bone adhesive to enhance healing and decrease recovery time in soft tissue ligament reconstruction.

Keywords: bone adhesive; bone cement; tendon-to-bone healing; ACL

Anterior cruciate ligament (ACL) ruptures often lead to knee instability and require reconstruction. Autologous bone–patellar tendon–bone grafts are popular because they allow for bone-to-bone healing in the femoral and tibial tunnels. However, the harvest of this graft is associated with significant donor site morbidity, including persistent patellofemoral pain, quadriceps weakness, and patellar tendonitis. Autologous tendon grafts, such as the semitendinosus and gracilis tendons, have minimal donor site morbidity and the highest initial tensile strength and stiffness of all graft choices. The major disadvantage with soft tissue grafts is the time required to allow secure tendon-to-bone healing for graft fixation. Several studies have shown that tendon-to-bone healing occurs more slowly and more incompletely than bone-to-bone healing. This raises concerns regarding the strength of fixation of the tendon within the bone tunnels and the subsequent risk for graft slippage and failure. Interventions that can accelerate and improve tendon-to-bone healing are attractive since they can potentially limit graft fixation failures, prevent slippage, and allow for early, aggressive rehabilitation.

The native ACL inserts on the tibia and femur through a direct insertion. Direct insertion sites are composed of 4 transitional zones: ligament, unmineralized fibrocartilage, mineralized fibrocartilage, and bone. This morphologic...
construct is not replicated after ACL reconstruction. Instead, the tendon graft heals in the bone tunnel with an interposed layer of fibrovascular scar tissue that is biomechanically inferior to a normal tendon-to-bone insertion.8,9,19,21 Over time, the surrounding bone grows into this interface tissue, while collagen fibrils become oriented perpendicular to the long axis of the tendon and anchor into the bone. This arrangement is similar histologically to the Sharpey fibers seen in indirect insertion sites, such as the medial collateral ligament of the knee. Because of the formation of scar tissue between the graft and bone early in the healing process, the fixation sites of tendon grafts are seen as the “weak link” in ACL reconstruction.

Bone cements are widely available for filling osseous defects in fracture repair. Recently there has been an effort to evaluate whether these products can aid in tendon-bone healing. Most of these studies have focused on calcium phosphate–based cements and have shown encouraging preliminary results.16,23 Osteocrete (Bone Solutions Inc, Dallas, Tex) is a magnesium-based, injectable bone adhesive currently in experimental use. Osteocrete has been shown in preliminary studies to have a peak tensile load to failure 3 times that of calcium-based bone cements in both bone-bone and tendon-bone attachments in cadaveric models.2 It has also been shown to increase the amount of callous formation in an equine metatarsal osteotomy model when compared with a calcium phosphate cement.26 While these preliminary studies are encouraging, the material’s ability to improve the healing of soft tissue to bone in vivo has not been studied.

The purpose of this study was to investigate the effect of an injectable, magnesium-based bone adhesive on tendon-to-bone healing in a rabbit ACL reconstruction model. We hypothesized that this material would act as an osteoconductive scaffold, leading to a reduction in fibrous tissue and increased bone and fibrocartilage formation at the healing tendon-bone interface, with an improvement in the biomechanical properties when compared to untreated controls at 3 and 6 weeks.

METHODS

Study Design

A total of 35 New Zealand White rabbits underwent bilateral ACL reconstruction surgery with semitendinosus autografts. The right limb received Osteocrete (Bone Solutions), a magnesium-based, injectable bone adhesive, while the left limb received no bone adhesive and served as control. Sixteen rabbits were sacrificed at 3 weeks, and the remaining 16 were sacrificed at 6 weeks. At each time point, 12 animals were used for biomechanical testing, and 4 were used for microcomputed tomography (μCT), scanning electron microscopy, and histology. Three animals were used for time 0 μCT analysis to evaluate tunnel fill with the bone adhesive.

Animal Model

This study used an established model of ACL reconstruction in the knee of skeletally mature male New Zealand White rabbits.13 The rabbits were obtained from a licensed United States Department of Agriculture dealer and were housed in the Facility for the Care of Laboratory Animals at our institution, in accordance with the standards established by the National Institutes of Health for the care and use of laboratory animals. Upon arrival, the animals were housed in individual cages and allowed free cage activity for 1 week before surgery. This study was approved by the Institutional Animal Care and Use Committee.

Surgical Procedure

Rabbits received no food or water 12 hours before surgery. Anesthesia was induced with ketamine (40 mg/kg) and acetylpromazine (0.5 mg/kg) delivered in a single syringe subcutaneously. Anesthesia was then maintained throughout the surgery via isoflurane inhalation through an endotracheal tube. Animals received ampicillin (25 mg/kg) 30 minutes before surgery for antibiotic prophylaxis.

A midline incision was made, and a lateral parapatellar arthrotomy was used to expose the ACL. A lateral arthrotomy was used to preserve the medial patellar retinaculum in an effort to minimize the risk of postoperative patellar dislocation. The semitendinosus tendon was then harvested and placed in saline-soaked gauze until preparation. Tunnels were drilled with a 2.78-mm-diameter drill bit through the femur and tibia at the insertion of the native ACL. In contrast to the established model of ACL reconstruction in New Zealand White rabbits, a slightly larger drill bit was used in this study to ensure adequate space for the bone adhesive.13 The graft was then passed through the bone tunnels to replace the ACL. The tunnels were irrigated with saline before application of the experimental agent.

The Osteocrete (Bone Solutions) bone adhesive was then prepared using a strict sterile technique. Twelve grams of the bone adhesive was mixed with 3 mL modified phosphate buffered saline in a 50-mL syringe as per the manufacturer’s protocol. The mixture was manually stirred for 2 minutes. When the material became viscous and began to harden, which took about 5 minutes, it was transferred into a 12-mL curved-tip syringe (Monoject; Tyco Healthcare Group LP, Mansfield, Mass) with approximately half of the tip cut off to form an opening measuring an eighth of an inch (no needle was used) and injected into the bone tunnels of the femur and tibia of the right knee. The bone tunnels were roughly 2 cm long, and about 1 mL of cement was injected into each tunnel from the extra-articular end. There were no problems with the viscosity of the cement during injection. The graft was passed back and forth to ensure even coating of the agent along the entire tunnel. Extravasated bone adhesive was cleaned using a saline-moistened sponge. The grafts were then secured to the periosteum and the surrounding soft tissues outside the femoral and tibial tunnels using 3-0 Ethibond sutures (Ethicon Inc, Somerville, NJ). After the graft was fixed, the remaining bone adhesive was used to “caulk” the exits of the bone tunnels. The wounds were then closed in layers, paying special care to ensure adequate closure of the lateral patellar retinaculum with 3-0 Ethibond.

Postoperatively, all animals were allowed free cage activity. They were given buprenorphine (0.05 mg/kg) subcutaneously for 3 days for pain control. The rabbits typically
had a mild limp for up to 2 weeks and regular pain-free activities after 2 weeks. Three animals were sacrificed immediately after the surgical procedure and served as time 0 controls to verify adequate tunnel fill with the bone adhesive. Sixteen animals were sacrificed at 3 weeks, and 16 animals were sacrificed at 6 weeks. These animals were tranquillized with acetylpromazine (0.4 mg/kg) 30 minutes before euthanasia to reduce stress. The animals were then euthanized with sodium pentobarbital 26% (“Sleepaway”; Fort Dodge Animal Health, Fort Dodge, Iowa) administered intravenously through the auricular vein.

Microcomputed Tomography Analysis

Upon necropsy at their respective time points, limbs were carefully dissected, and axial sections were obtained from the tendon-to-bone interfaces at the tibial and femoral tunnels. These sections were fixed in 10% neutral buffered formalin. Microcomputed tomography (μCT) analysis at 19 μm of isotropic resolution was subsequently performed using an MS-8 In Vitro Specimen Scanner (GE Medical System, London, Ontario, Canada). Each scan included a phantom containing air, saline, and an SB-3 bone analog (1.18 g/cc) for calibration of image Hounsfield units to tissue mineral density. Individual CT slices were reconstructed using a modified Parker algorithm with a resolution of 24 μm. Images were thresholded using 25% of the mineral attenuation of the cortical bone for each specimen. Regional analyses of the thresholded scans were performed using the system software (MicroView; GE Healthcare Technologies, Waukesha, Wis). A 4.5 × 6.0-mm cylindrical volume of interest (VOI) was centered along the longitudinal axis of the bone tunnel in the middle portion of the tunnel. The VOI contained the graft and the bone surrounding the tunnel, as all tunnels were drilled with a 2.78-mm drill bit. Total bone volume (TBV, mm$^3$) and bone volume fraction (BV/TV) were calculated based on the number of bone voxels compared with the total number of voxels in the VOI. Tissue mineral content (TMC, mg) and bone mineral content (BMC) were also determined based on the known standard. Trabecular architecture was characterized by the direct trabecular thickness (TbTh, μm) measurements. For the 3 time 0 specimens, qualitative assessments were made to determine the extent of the canal filled with the bone adhesive.

Histomorphometric Analysis

The same specimens that underwent μCT analysis were then decalcified in Immunocal (Decal, Congers, NY) and embedded in paraffin. Five-micrometer-thick sections were cut perpendicular to the bone tunnel and stained with hematoxylin and eosin and safranin-O/fast green for routine histologic evaluation using light microscopy (Eclipse E800; Nikon, Melville, NY). Digital images were taken using a SPOT RT camera (Diagnostic Instruments, Sterling Heights, Mich). Computerized image analysis (Image J, NIH) was then used to measure the width of the tendon-bone interface and the area of new cartilage formation. To determine the interface width, the tendon-to-bone interface was divided into 4 quadrants. Each histologic section was taken at the midportion of the tunnel, approximately 1 cm from the articular surface. In each of the 4 quadrants, the interface width was measured as the distance between the edge of the bone tunnel and the outer tendon as determined under 100× magnification. Four separate measurements were made in each of the quadrants for a total of 16 measurements for each specimen. The interface width was then determined by averaging these numbers for each specimen (Figure 1). The area of new cartilage formation was determined by outlining the area of metachromasia on the safranin-O slides at 40× magnification. The total area of metachromasia was recorded for each specimen. Three observers performed the histomorphometric measurements together as a group and arrived at a consensus.

Biomechanical Analysis

The limbs that were used for biomechanical analysis were frozen at –80°C until testing. At the time of testing, the limbs were thawed, and all soft tissue was removed except the grafted tendon. All scar tissue and sutures at the tunnel exits were carefully removed so as to determine the effects of the bone adhesive on the strength of healing and eliminate any confounding factors such as suture material. The femur–ACL graft–tibia complexes were fixed in specially designed clamps allowing tensile loading along the axis of the graft in a materials testing machine. A preload of 1 N was applied. After cyclic preconditioning of the constructs between elongation limits of 0 and 0.75 mm, a load-to-failure test was performed at an elongation rate of 10 mm/min. The failure load was recorded, and stiffness (N/mm) was calculated from the slope of the linear region of the load-displacement curve between 1.5 and 2 mm of elongation. The site of graft failure (femoral tunnel, mid-substance, or tibial tunnel) was recorded. This testing protocol has been used in previous studies from our laboratory.

Statistical Analysis

Before this study, a power analysis was performed. In our previous work with this rabbit ACL reconstruction model,
we found that the average width of the tendon-bone scar interface was approximately 130 μm ± 20 μm. Using these estimations, 4 specimens per group provided a power of .80 to detect a 30% difference in tendon-bone interface width with α = .05. For biomechanical testing, our prior testing with this model found an average tensile strength of 20 N at 28 days after repair, with a standard deviation (SD) of 5.0 N. For the current study, an increase in strength of 40% would be considered clinically significant. Using these estimations, a power of .80 is achieved using 12 specimens per group with α = .05 for biomechanical testing. The power calculation was performed using SigmaStat (Jandel Scientific, San Rafael, Calif). The histomorphometry, μCT, and biomechanical data were all compared between the experimental and control limbs using a paired Student t test (Excel; Microsoft, Redmond, Wash). Statistical significance was set at P < .05.

RESULTS

Gross Observations

Upon necropsy, the knee joints of all limbs contained clear serous fluid, but there were no signs of gross infection. Synovitis was seen in all limbs at 3 weeks (no noticeable difference between control and experimental), but by 6 weeks, the synovitis had subsided. There were no obvious chondral injuries noted. Although the bone cement is exothermic, there was no evidence of graft or tissue necrosis on histologic testing. Moreover, no cement residue was found on the cartilage or in the intra-articular space. Five grafts failed to heal: 1 in the control limb of an animal sacrificed at 3 weeks; 1 from the experimental limb at 3 weeks; 1 from an experimental limb at 6 weeks; and 2 from control limbs at 6 weeks. The location of graft failure was intra-articular (midsubstance) in all limbs. The specimens with failed grafts were deducted from the biomechanical testing groups. Therefore, there were 11 specimens available for biomechanical testing in the control group at 3 weeks, the bone adhesive group at 3 weeks, and the bone adhesive group at 6 weeks; and there were 10 specimens available in the control group at 6 weeks. Four specimens in each group remained available for histomorphometric analysis. In the 3 animals that were sacrificed at time 0, the bone adhesive had not completely hardened by the time of necropsy. The time from surgery to necropsy was approximately 30 minutes for all animals in the time 0 group. In vitro, the bone adhesive had completely hardened after 20 minutes, suggesting that perhaps the blood and synovial fluid in vivo may delay hardening.

Microcomputed Tomography

Three specimens underwent μCT at time 0 to confirm adequate tunnel fill with the bone adhesive. Qualitative analysis of these scans confirmed that the bone adhesive had circumferentially coated the graft throughout the length of the tunnel (Figure 2). By 6 weeks, the TBV was significantly greater in the tibial tunnels of the experimental limbs when compared with the control limbs (27.0 ± 8.1 mm³ for the experimental tibia, 12.0 ± 3.6 mm³ for the controls; P = .03). There were no differences in TBV between the experimental and control femurs at 6 weeks, nor were there any differences in either bone at 3 weeks (Figures 3 and 4). Furthermore, there were no differences between any groups for TMC, BMC, BV/TV, or TbTh (data not shown).
Histomorphometric Analysis

All tendon grafts healed by the formation of fibrovascular interface tissue at the tendon-bone interface. There was progressive new matrix formation and bone in-growth by 6 weeks. This resulted in the establishment of collagen fiber continuity between tendon and bone in all samples (Figure 5). An enthesis with fibrocartilage between tendon and bone circumferentially was not observed in any sample. However, there were several samples in which a portion of the tendon-to-bone interface replicated the fibrocartilaginous transition zone of the native insertion site at 6 weeks. Three of the 4 femoral specimens (75%) and all 4 of the tibial specimens (100%) treated with the bone adhesive exhibited fibrocartilage formation. In the control group, fibrocartilage was found in only 1 of the 4 specimens in both the tibia (25%) and femur (25%). In 1 sample that received the bone adhesive in the 6-week group, a granuloma was observed in the tendon-bone interface. This was the only example of the adhesive potentially inciting an inflammatory response. The adhesive does not have any known side effects or toxicity.

Treatment with the bone adhesive resulted in less apparent scar tissue formation at the tendon-bone interface as evidenced by interface widths at 6 weeks (Figure 6). There was a reduction in the interface width of 44% for the femur and 50% for the tibia in the limbs that received Osteocrete (Bone Solutions) when compared with controls. The mean interface width for the femurs in the experimental group at 6 weeks was 69.5 ± 36.2 μm, while the mean width for the control femurs at 6 weeks was 156.9 ± 57.3 μm (P = .04). The mean interface width for the tibia in the experimental group at 6 weeks was 75.8 ± 25.1 μm, while the mean width for the 6-week control tibia was 150.5 ± 42.2 μm (P = .04). There were no differences between groups at 3 weeks.
The bone adhesive also resulted in more cartilage formation as evidenced by the area of metachromasia at 6 weeks (Figure 7). The mean area of metachromasia in the experimental 6-week femurs was $79.556.2 \pm 61.664.0 \mu m^2$ compared with $2806.2 \pm 6873.7 \mu m^2$ for the control femurs at 6 weeks ($P < .05$). The mean area in the experimental 6-week tibia was $41.979.2 \pm 38.345.7 \mu m^2$, while the control 6-week tibia contained $2806.2 \pm 6873.7 \mu m^2$ ($P = .04$). No differences were seen between the groups at 3 weeks.

**Biomechanical Testing**

The mean load-to-failure for the experimental limbs at 6 weeks was twice that seen for the control limbs at the same time point ($71.8 \pm 31.8$ N for the experimental limbs compared with $43.4 \pm 14.8$ N for controls; $P = .04$). There were no differences between the groups at 3 weeks ($36.1 \pm 9.1$ N for the 3-week experimental limbs, $36.7 \pm 9.5$ N for controls; $P = .90$). There were no differences between groups at either time point in stiffness of the bone–tendon graft–bone construct (Figure 8). All specimens failed at the graft-tunnel junction, with an equal number of failures occurring from the tibial and femoral sides.

**DISCUSSION**

It is well established that tendon grafts heal in a bone tunnel with an intervening layer of fibrovascular scar tissue. This scar tissue is mechanically inferior to normal tissue and represents a “weak link” after surgical reconstruction. As these tissues remodel with time, bone from the tunnel grows into the fibrous interface tissue and confers mechanical strength. For these reasons, there is much interest in developing interventions that can accelerate and improve bone in-growth. Several experimental agents have been studied, including the application of bone morphogenetic protein-2 (BMP-2),$^{1,13,14}$ transforming growth factor-β1 (TGF-β1),$^{27}$ the antosteoclastogenic protein osteoprotegerin,$^6$ stem cells,$^{12,17}$ periosteum,$^{28}$ transcutaneous ultrasound,$^{25}$ and calcium-based cements.$^{13,16,23}$

In this study, we evaluated the ability of a magnesium-based bone adhesive to improve tendon-to-bone healing in a rabbit ACL reconstruction model. We found that this material had a positive effect in terms of limiting scar formation, promoting the regeneration of a fibrocartilage insertion site, and increasing the amount of bone formed in the tunnels at 6 weeks. These histologic findings correlated with improved biomechanical properties in terms of load-to-failure.

The use of bone cements to augment bone in-growth into the scar interface is an attractive option because these materials are readily available and relatively inexpensive.
when compared with other biologic therapies. Using a similar model, Tien et al. evaluated the ability of a calcium-phosphate bone cement to augment tendon-to-bone healing. They found the cement caused diffuse bone ingrowth into the interface tissue at early time points when compared with untreated controls. Furthermore, they showed that ultimate loads to failure were 3 times that of the control group at 1 week and approximately twice that of the control group at 2 weeks. Biomechanical testing at later time points was not conducted. Matsuzaki et al. hybridized semitendinosus tendon grafts with a calcium phosphate–containing solution in vitro before using them to perform ACL reconstructions in rabbits. They noted an abundance of osteoclasts and osteoblasts around the tendon-bone interface by 2 weeks, with newly formed bone and cartilage around the tendon grafts by 3 weeks. However, biomechanical testing was not conducted.

We have previously studied the ability of recombinant human bone morphogenetic protein-2 (rhBMP-2) to improve bone in-growth in the same rabbit ACL model. In our first study, we found that rhBMP-2 on a collagen sponge resulted in early osteoclastic resorption around the tunnel edges, followed by extensive formation of new bone that resulted in a stronger tendon-bone interface. In a subsequent study, calcium phosphate cement was used as a carrier for the application of rhBMP-2. The calcium phosphate cement was effective in limiting the early resorptive phase seen with the collagen sponge. The controls treated with the calcium phosphate cement alone showed superior healing compared to the historical controls using a sponge carrier alone. These findings suggested that perhaps an osteoconductive scaffold alone might prove sufficient to augment tendon-to-bone healing. However, calcium phosphate acts more like a grout than a glue. These properties make it an ideal choice to resist compressive forces that are seen in bone defect models but might not be the ideal material to resist the tensile forces seen at the tendon-bone interface.

The bone adhesive used in this study, Osteocrete (Bone Solutions), is composed of calcium, phosphate, and magnesium. Magnesium oxide comprises 41% of the weight of the powder form of Osteocrete and 32% by weight with the addition of the modified phosphate-buffered saline. The calcium phosphate component provides an osteoconductive biologic scaffold onto which new bone can form. The magnesium gives the cement an adhesive quality that theoretically allows it to resist tensile forces at time 0, thereby potentially limiting graft-tunnel motion. In preliminary in vitro testing of the material’s ability to adhere tendon-to-bone at time 0, the magnesium-based bone adhesive was more than 3 times stronger than a commercially available calcium phosphate cement. In vivo testing in an equine metatarsal osteotomy model has shown that application of the magnesium-based bone adhesive results in more callus formation and a quicker time to union when compared with a calcium phosphate cement. However, no differences were seen in biomechanical testing at 7 weeks.

While these characteristics offer theoretical advantages, further study is required to evaluate the clinical applicability of this material for tendon-to-bone repair. We observed that the bone adhesive had not completely hardened by the time of necropsy on the 3 time 0 animals. Our finding of significantly improved attachment strength at 6 weeks is likely due to the osteoconductive properties of the material. Earlier time points should be studied to determine if the adhesive properties alone improve graft fixation strength. However, it is also possible that the adhesive properties of the material alone improved eventual graft healing by minimizing detrimental graft-tunnel motion. At any rate, the adhesive did appear to have a positive biological effect on tendon-to-bone healing as evidenced by superior histologic, radiographic, and biomechanical results at 6 weeks. The average ultimate load-to-failure for the limbs receiving the bone adhesive at 6 weeks was 71.8 ± 31.8 N, while the average load seen in our previous study with calcium phosphate cement alone at 8 weeks was 38.6 ± 18.0 N. Conclusive comparisons cannot be made since these represent historical controls; however, it appears that any augmented healing is still far from re-creating the biomechanics of the native ACL insertion at these time points.

While there was more fibrocartilage at the interface in limbs treated with the bone adhesive, no specimens had fibrocartilage circumferentially around the graft as seen in normal direct-ligament insertion sites. This was seen despite μCT analyses at 0 time that showed circumferential fill of the tunnel with the bone adhesive. This finding is most likely due to the varying mechanical stresses that are placed on different portions of the tendon-bone interface. We have recently shown that graft-tunnel motion can affect graft healing in a bone tunnel in the same rabbit model. Further studies are needed to define the role that graft-tunnel motion, or lack thereof, plays in the healing process.

We used μCT to objectivley determine the amount of new bone formed in the tibial and femoral tunnels. While μCT has been used to assess bone formation in a rotator cuff model of tendon-to-bone healing, we believe this is the first to use it to determine the amount of bone formed in a tunnel. We found the tibias of the 6-week animals that received the bone adhesive had significantly greater bone volume compared to controls. We did not find a significant difference between experimental and control femurs at this time point. This is most likely due to the high variability seen in this group that limited statistical power. In past studies, we have measured new bone formation using semi-quantitative histology, which has the potential to introduce errors because of interobserver variability. We found that μCT allowed accurate, precise quantification of osseointegration of the tendon graft in a bone tunnel in this model.

We acknowledge several limitations to our study. The use of a rabbit model makes extrapolation into human patients difficult. While the technique of ACL reconstruction in this model has been well established, rabbits place unusual stresses on their grafts because they sit with their knees in hyperflexion. As discussed earlier, the effect these stresses have on healing is not completely understood. This may have contributed to the 5 graft failures seen on necropsy and the inconsistent presence of fibrocartilage at the interface. Additionally, it is unclear what the long-term effects on hardening would be if this were done in a fluid-filled
arthroscopic environment. Also, there were high variances in the semiquantitative histology and μCT data as evidenced by large standard deviations that limited the statistical power and raised the possibility of a type II error. This could explain why no differences were seen between groups at 3 weeks. However, for most of the outcome variables at 3 weeks, the mean values were so similar that it is difficult to imagine significance emerging with more samples. Finally, the study groups had been powered according to prior biomechanical testing data. However, 2 specimens at 3 weeks were lost due to graft failure. This resulted in suboptimal power and raises the possibility of a type II error.

In summary, the results of this study indicate that a magnesium-based bone adhesive can improve tendon-to-bone healing in a rabbit model. We found that this material can induce fibrocartilage formation, limit fibrous tissue for tendon-to-bone healing in a rabbit model. We found that this material can induce fibrocartilage formation, limit fibrous tissue formation at the healing tendon-bone interface, and increase osteointegration at 6 weeks. It may eventually be possible to use this bone adhesive clinically to augment tendon-to-bone healing, potentially leading to increased attachment strength and a diminished risk of graft failure or slippage.

REFERENCES


